TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) insider Tamer I. Khayal sold 4,947 shares of the business's stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $80.36, for a total transaction of $397,540.92. Following the sale, the insider now owns 25,185 shares of the company's stock, valued at $2,023,866.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
TransMedics Group Stock Up 10.2 %
TMDX opened at $85.04 on Friday. The firm's fifty day moving average price is $82.28 and its 200 day moving average price is $70.58. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $99.63.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm's quarterly revenue was up 158.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.21) earnings per share. On average, equities research analysts anticipate that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
Several research firms have issued reports on TMDX. JPMorgan Chase & Co. boosted their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. Morgan Stanley boosted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 28th. Oppenheimer boosted their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 27th. Finally, Piper Sandler began coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They set an "overweight" rating and a $95.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $102.00.
Read Our Latest Stock Report on TransMedics Group
Institutional Trading of TransMedics Group
Several institutional investors have recently added to or reduced their stakes in TMDX. Comerica Bank acquired a new stake in shares of TransMedics Group during the third quarter worth $34,000. Global Retirement Partners LLC acquired a new stake in shares of TransMedics Group during the third quarter worth $38,000. Cutler Group LLC CA raised its holdings in shares of TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company's stock worth $38,000 after purchasing an additional 600 shares during the period. Ancora Advisors LLC acquired a new stake in shares of TransMedics Group during the first quarter worth $38,000. Finally, First Horizon Advisors Inc. raised its holdings in shares of TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock worth $41,000 after purchasing an additional 169 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
